[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,224,894
  • Shares Outstanding, K 140,857
  • Annual Sales, $ 829,450 K
  • Annual Income, $ -1,630 K
  • EBIT $ -222 M
  • EBITDA $ -204 M
  • 60-Month Beta 1.28
  • Price/Sales 13.23
  • Price/Cash Flow 661.97
  • Price/Book 18.48

Options Overview Details

View History
  • Implied Volatility 62.42% (-2.35%)
  • Historical Volatility 51.41%
  • IV Percentile 25%
  • IV Rank 29.41%
  • IV High 100.09% on 07/21/25
  • IV Low 46.72% on 07/07/25
  • Expected Move (DTE 34) 10.46 (13.12%)
  • Put/Call Vol Ratio 0.95
  • Today's Volume 1,367
  • Volume Avg (30-Day) 1,470
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 37,792
  • Open Int (30-Day) 35,283
  • Expected Range 69.24 to 90.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.16
  • Number of Estimates 8
  • High Estimate $-0.33
  • Low Estimate $-1.52
  • Prior Year $-1.26
  • Growth Rate Est. (year over year) +7.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.42 +16.18%
on 04/16/26
82.26 -4.78%
on 05/14/26
+7.38 (+10.40%)
since 04/15/26
3-Month
54.02 +45.00%
on 03/13/26
82.26 -4.78%
on 05/14/26
+14.51 (+22.74%)
since 02/13/26
52-Week
14.30 +447.76%
on 07/22/25
82.26 -4.78%
on 05/14/26
+62.99 (+410.63%)
since 05/15/25

Most Recent Stories

More News
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation...

ARWR : 78.33 (-1.71%)
Arrowhead Pharmaceuticals Q2 Earnings Call Highlights

Arrowhead Pharmaceuticals (NASDAQ:ARWR) highlighted continued commercial traction for REDEMPLO and outlined multiple anticipated clinical catalysts in the second half of 2026 as the company reported fiscal...

ARWR : 78.33 (-1.71%)
Arrowhead Research: Fiscal Q2 Earnings Snapshot

Arrowhead Research: Fiscal Q2 Earnings Snapshot

ARWR : 78.33 (-1.71%)
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

- Conference Call and Webcast Today, May 7, 2026, at 4:30 p.m. ET

ARWR : 78.33 (-1.71%)
Arrowhead's Commercial Launch Looks Solid But Obesity Trial Design Remains the Real Question

Barchart Research What to Expect from ARWR Earnings ARWR Generated May 6, 2026 Current Price $79.14 EPS Estimate $$-1.25 Consensus Rating Strong Buy Average Move 10.58% Arrowhead's Commercial Launch Looks...

ARWR : 78.33 (-1.71%)
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH - Phase 1 data published in The New England...

ARWR : 78.33 (-1.71%)
MDGL : 539.89 (+4.05%)
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference –...

ARWR : 78.33 (-1.71%)
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed and clinically diagnosed adult patients with FCS ...

ARWR : 78.33 (-1.71%)
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

– If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed adult patients with FCS ...

ARWR : 78.33 (-1.71%)
Stocks Fall as Iran Refuses to Attend Peace Talks

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.63%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.42%. June E-mini...

MSTR : 182.40 (-2.44%)
ALK : 37.23 (-2.44%)
UAL : 94.20 (-1.90%)
CVS : 96.90 (-0.26%)
B : 41.73 (-3.32%)
HL : 18.35 (-5.66%)
DHI : 137.70 (-1.19%)
CDE : 18.40 (-5.15%)
GLXY : 30.70 (-4.18%)
MRK : 113.45 (+0.04%)
TSCO : 30.21 (-0.92%)
$IUXX : 29,580.30 (+0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

3rd Resistance Point 85.39
2nd Resistance Point 83.82
1st Resistance Point 81.76
Last Price 78.33
1st Support Level 78.13
2nd Support Level 76.56
3rd Support Level 74.50

See More

52-Week High 82.26
Last Price 78.33
Fibonacci 61.8% 56.30
Fibonacci 50% 48.28
Fibonacci 38.2% 40.26
52-Week Low 14.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.